Cover Image
市場調查報告書

半乳糖凝集素-1:開發中產品分析

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365799
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
半乳糖凝集素-1:開發中產品分析 Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 60 Pages
簡介

本報告提供以半乳糖凝集素-1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

半乳糖凝集素-1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Galectin Therapeutics, Inc.
  • PepTx, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0317TDB

Summary

Global Markets Direct's, 'Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016', provides in depth analysis on Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein)
  • The report reviews Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Overview
  • Therapeutics Development
    • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Stage of Development
    • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Therapy Area
    • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Indication
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Companies
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Universities/Institutes
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Companies Involved in Therapeutics Development
    • Galectin Therapeutics, Inc.
    • PepTx, Inc.
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Drug Profiles
    • CNC-225 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-CT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Galectin-1 for B-Cell Non-Hodgkin Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTX-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Dormant Projects
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Discontinued Products
  • Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Featured News & Press Releases
    • Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
    • May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis
    • May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis
    • May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference
    • Feb 24, 2016: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis
    • Jan 07, 2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website
    • Nov 11, 2015: Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting
    • Oct 19, 2015: Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda in Patients With Metastatic Melanoma
    • Sep 24, 2015: Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02
    • Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis
    • Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
    • Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH
    • Jun 29, 2015: Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
    • May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
    • Mar 24, 2015: Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Pipeline by PepTx, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top